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ABSTRACT – PURPOSE. In vitro skin/membrane permeation profiling of topical pharmaceuticals is an 
important overall quality attribute in the evaluation of product consistency and it is also used for IVIVR (in vitro 
- in vivo relationship) purposes in product development and change control. Franz diffusion cell (FDC) 
experiments are emerging as a generally accepted methodology in this field, where the choice of operational 
conditions requires a data-supported justification towards the discriminating power of the test. A response 
function is therefore proposed to objectively quantify the discriminating power. METHODS. We evaluated the 
usefulness of the proposed response function by studying one of the operational conditions, i.e. the influence of 
receptor medium composition, on the FDC in vitro penetration behaviour of the model compound testosterone 
formulated in four different topical preparations, using both artificial membranes and dermatomed human skin. 
A second application is a FDC test system for spilanthol. RESULTS. From the obtained cumulative amount of 
the active (testosterone or spilanthol) in the receptor fluid versus time curves, the permeability coefficient Kp of 
testosterone from each formulation was calculated. The evaluation of the discriminating power of the different 
media was performed using our new objective response function based upon an equal spread criterion of 
normalised Kp values. CONCLUSION. The proposed new criterion was found to be useful for the rational 
design of an in vitro diffusion test for transdermal pharmaceuticals. We demonstrated significant differences in 
discriminating power between the different media used: (a) for testosterone-containing formulations, it was 
shown that HPBCD-containing media are more discriminative compared to ethanol- or BSA-containing media; 
(b) for spilanthol-containing formulations, PBS containing formulations also gave better discriminating results 
than ethanol-based receptor media. 
__________________________________________________________________________________________ 
 
INTRODUCTION 
 
The commercialization of transdermal drug delivery 
systems (TDS) like patches and gels has resulted in 
diverse products (1) such as nitroglycerin for angina 
pectoris, scopolamine for motion sickness, fentanyl 
for pain control, nicotine for smoking cessation, 
estrogen for hormone replacement therapy, 
testosterone for male hypogonadism, clonidine for 
hypertension, lidocaine for topical anaesthesia, and 
ethynylestradiol for contraception. Over the last 
decades, transdermal drug delivery has become 
increasingly popular for many reasons (2): the 
availability of well-characterized formulation 
technology (3), the development of a 
biopharmaceutical, pharmacokinetic and 
pharmacodynamic science base to allow definition  
 
 
and study of important safety and efficacy issues 
that are related to TDS, the opportunities afforded  
by TDS for better patient compliance and more 
consistent and reliable drug concentrations over 
protracted dosing periods, a high degree of 
acceptance by both patients and health care 
professionals and the development or extension of 
market exclusivity for off-patent drugs or drugs that 
are losing patent or exclusivity protection.  
_________________________________________ 
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As a result, the pharmaceutical industry is investing 
increasing amounts of money and resources on the 
development of new products that reversibly 
overcome the skin barrier.Although a new 
transdermal product is only of value if the clinical 
pharmacokinetic profile delivers the appropriate 
pharmacodynamic response needed for the 
treatment of the patient, preclinical assessments 
strongly guides the product development. These 
include as well in vitro experiments for determining 
the flux of the compound across skin or membranes 
during feasibility studies, as in vivo evaluation in 
animal models (4). The aim of the in vitro 
experiments in transdermal delivery is to evaluate 
the penetration of a molecule through the skin. 
Typically, this is achieved by using a variety of skin 
diffusion cells and different experimental protocols. 
There have been numerous recommendations, and 
some of them have been selected as guidelines by 
both regulatory entities and committees of 
interested parties. The most widely known of these 
guidelines are “Guideline Number 428 on the 
Conduct of Skin Absorption Studies” by the 
Organization for Economic Cooperation and 
Development (OECD) (5), the  European Centre for 
Ecotoxicology and Toxicology of Chemicals 
(EXETOC) workshop on “Methods for assessing 
percutaneous penetration” (6), the “Guidelines for 
Percutaneous Penetration / Absorption” by the 
European Cosmetic Toiletry and Perfumery 
Association (COLIPA) (7), the American 
Association of Pharmaceutical Scientists/Food and 
Drug Administration (AAPS/FDA) workshop on 
the performance of in vitro skin penetration studies 
(8) and the FDA “Guidance for the Industry on 
Non-sterile Semisolid Dosage Forms” (9). 
Irrespective of the guidance followed, the 
techniques used must be carefully considered as 
several variables such as the type of cell system, the 
skin source, skin integrity and viability, skin 
preparation, composition of receptor fluid and even 
the way as results are calculated can influence the 
outcome and final conclusions (10). 
Determination of the release rate of the active 
pharmaceutical ingredient (API) and/or specific 
excipients from the formulation, i.e. its diffusion in 
and through a biological or artificial membrane 
contacting a receptor fluid, is not only an important 
parameter for characterizing its transdermal 
behaviour, but it can also be considered as a global 
overall quality attribute which is valuable in the 
development of a suitable formulation or in the 
evaluation of possible changes in formulation 
composition (11), production parameters and shelf-
life stability. Therefore, the regulatory health 
authorities are generally requesting these diffusion-
release tests in the pharmaceutical dossier submitted 
to obtain the marketing authorisation. The following 
points should be considered when developing the in 
vitro release procedure for dermatological products 
(12): (a) the method(s) developed should assure 
batch-to-batch quality for the product, (b) the 
method should be general enough and should be 
applicable to all products that are (and will be) 
marketed, (c) the method should be discriminative 
enough to detect manufacturing changes that (may) 
influence product performance and (d) the method 
should be simple, reliable, reproducible and capable 
of automation. However, the development of such a 
global functionality quality test is currently often a 
matter of discussion due to a certain lack of 
standardisation, missing generally accepted criteria, 
incomplete understanding of fundamental theory 
and its applications, regulatory immaturity and the 
different objectives which are sometimes mixed up 
(quality-consistency versus in-vitro-in-vivo 
correlations). Whatever the context, however, a key 
aspect is the discriminating power of the test (13), 
i.e. the ability to distinguish different preparations 
as separate items. Therefore, we propose a new 
criterion assessing the discriminating power 
between different FDC-tests, based on 
experimentally obtained Kp values. The 
applicability of this criterion is demonstrated by the 
systematic evaluation of different FDC receptor 
media on the transdermal and transmembrane 
behaviour of the test compound testosterone, 
previously defined as a suitable model compound 
for skin penetration studies (14). A second 
application given here is the skin FDC test system 
for spilanthol containing formulations. 
 
METHODS 
 
Products examined 
Three testosterone-containing topical products were 
purchased from the Ghent university hospital 
pharmacy: Testim® 50 mg gel (Ipsen, Merelbeke, 
Belgium), Androgel® 50 mg gel (Laboratoires 
Besins International, Paris, France) and Tostrex® 
2% gel (Strakan, Tredegar, UK). Androtiv® 2% gel 
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(Anastore, Geneva, Switzerland) was obtained from 
the internet. 
 
Reagents 
0.01 M phosphate buffered saline (PBS) and 
CaCl2·H2O were purchased from Sigma (St. Louis, 
MO, USA). Bovine serum albumin (BSA), Na2SO4, 
KH2PO4, K2HPO4, MgSO4 and NaOH were bought 
from Merck (Darmstadt, Germany). NaCl, KCl, 
MgCl2·6H2O and NaHCO3 were obtained from 
UCB (Leuven, Belgium). HPLC gradient grade 
acetonitrile and methanol came from Fisher 
Scientific (Leicestershire, UK). LC-MS grade 
formic acid and HPLC-grade testosterone were 
purchased from Fluka (Buchs, Switzerland). 
Hydroxypropyl-β-cyclodextrine (HPBCD) and HCl 
were obtained from Acros Organics (Geel, 
Belgium). Ethanol, denatured with up to 5% ether, 
was bought from Chem Lab (Zedelgem, Belgium). 
Water was purified using an Arium 611 purification 
system (Sartorius, Göttingen, Germany) resulting in 
ultrapure water of 18.2 MΩ.cm quality. 
 
Liquid chromatography 
The testosterone content in the receptor fluid was 
assayed using a validated HPLC-UV method (15). 
Briefly, the HPLC apparatus consisted of a Waters 
Alliance 2695 separation module and a Waters 2996 
photodiode array detector (DAD) controlled by 
Empower 2 software (all Waters, Millford, USA). 
20 µL of each sample was injected onto a 
Lichrospher 100 RP C18 (125 mm x 4 mm, 5 µm 
particle size) column (Merck, Darmstadt, Germany) 
maintained at 30°C. Testosterone was eluted by a 
degassed isocratic mobile phase consisting of a 
mixture of 50% (A) 0.1% m/V formic acid in water, 
and 50% (B) 0.1% m/V formic acid in acetonitrile 
at a flow rate of 1 ml/min. UV detection was done 
at 254 nm. 
 
Preparation of receptor media 
Ethanol/H2O (30:70, V/V) was used as a reference 
receptor medium. Phosphate buffered saline was 
prepared according to the suppliers (Sigma) 
instructions, resulting in a 0.01 M solution at pH 
7.4. Artificial human sweat (SS) was prepared 
according to Shimamura (16). Simulated body fluid 
(SBF) was prepared as described by Dorozhkin 
(17). The exact composition is given in Table 1. To 
assure a good solubility of testosterone, a 
solubilizer was added. This was either 5% m/V 
BSA or 0.5% m/V HPBCD. 
 
Table 1. Composition of the physiological receptor 
media used (in mM). 
Component PBS SS SBF 
NaCl 138.00 49.96 136.80 
KCl 2.70 - 3.00 
CaCl2 - 0.15 2.50 
MgSO4 - 1.00 - 
MgCl2 - - 1.50 
Na2SO4 - - 0.50 
NaHCO3 - - 4.20 
KH2PO4 1.43 7.50 1.00 
Na2HPO4 8.57 - - 
 
 
Determination of testosterone solubility in the 
receptor media 
Excess testosterone was added to 2 ml of each 
receptor medium used and the mixture was 
incubated for 48 hours at 32°C with continuous 
shaking. The undissolved testosterone was removed 
by temperature-controlled centrifugation at 20 000 
g. 500 µL of the clear supernatant was transferred to 
a new tube and an equal volume of acetonitrile was 
added. After 10 minutes of shaking at room 
temperature, the samples were centrifuged for 10 
min at 20 000 g and the clear supernatant was 
transferred into glass HPLC vials. All tubes and 
pipettes used were preheated to 32°C in an oven. 
All experiments were performed in six-fold, except 
for EtOH/H2O as a solvent, where only three 
measurements were made. 
 
Permeation study 
The permeation of testosterone through both human 
skin and the artificial membrane was determined 
using static Franz diffusion cells (Logan 
Instruments Corp., New Jersey, USA) with a 
calibrated receptor compartment of 5 mL equipped 
with a sampling port. All conditions were 
performed in triplicate using a randomized blocked 
design. For the skin experiments, excised human 
skin from three different female patients (52 ± 7 
years old, mean ± standard deviation), who had 
undergone an abdominoplasty procedure, was used 
in such a way that each block of experiments was 
performed using skin from one donor. After 
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cleaning the skin with 0.01 M PBS pH 7.4 and 
removal of the subcutaneous fat, the skin samples 
were wrapped in aluminium foil and stored at -20°C 
for not longer than 3 months. Just before the start of 
the experiments, the skin samples were thawed and 
dermatomed to a pre-set thickness of 400 µm. The 
experimentally obtained thickness was determined 
using a micrometer (Mitutoyo, Tokyo, Japan). Skin 
samples or hydrophilic mixed cellulose esters filter 
sheets with 0.05 µm pore size (VMWP; Millipore, 
Schwalbach, Germany) were sandwiched between 
the donor (upper) and the receptor (lower) chambers 
of the diffusion cell. The receptor compartment was 
filled with receptor medium, making sure all air 
under the skin/membrane was removed. The whole 
assembly was fixed on a magnetic stirrer and the 
solution in the receptor compartment was 
continuously stirred using a Teflon coated magnetic 
stirring bar (400 rpm). Before starting the skin 
experiments, skin impedance with PBS in the donor 
chamber was measured using an automatic micro-
processor controlled LCR Impedance Bridge 
(Tinsley, Croydon, U.K.) to ensure that there was 
no skin damage. Skin pieces with an impedance 
value below 20 kΩ were discarded and replaced. A 
quantity of the formulation corresponding to 3 mg 
of testosterone was topically applied to the surface 
of the skin/membrane and carefully spread to 
achieve complete coverage. Smaller quantities of 
the formulations did not guarantee the full skin 
coverage. The donor compartment was then covered 
with parafilm (American National Can™, Chicago, 
USA) and the temperature of the receptor 
compartment was kept at 32 ± 2°C by a water 
jacket. The available diffusion area was 0.64 cm². 
Samples (200 µL) were drawn at regular time 
intervals from the sampling port (0, 0.5, 1, 1.5, 2, 4, 
8, 12, 18, 21 and 24h) and were immediately 
replaced by 200 µL fresh solution. The analytically 
determined testosterone assay values were 
correspondingly corrected for the replenishments. 
 
Data analysis 
The skin permeation parameters were calculated 
from the plot of cumulative amount testosterone 
permeated as a function of time. Steady-state flux 
(J) was obtained from the slope of the linear portion 
of the curve. The permeability coefficient Kp was 
calculated using the following equation: 
(1) 
 
where Cd is the concentration of the drug in the 
dose formulation. 
In case of the artificial membranes, a bending 
point was observed, i.e. two different slopes (J-
values). Hence, an initial Kp from the first part of 
the curve and a final Kp from the second part of the 
curve was calculated. 
All Kp values thus obtained (i from 1 to 20 for 
each of the 3 membrane systems: skin, initial- and 
final artificial membrane) were rescaled within each 
membrane system using the following 
normalization equation, resulting in a distribution 
between 0 and 1: 
 (2) 
 
where K’pi is the normalised Kp value for 
experiment i, Kpmin and Kpmax are the minimal and 
maximal values for Kp that were found over the 
total number of experiments (n).An overall response 
function F(Kp) reflecting the formulation-
discriminating power of the system was defined as 
the percentage equal-spread of the normalised Kp-
values obtained for the different formulations (in 
our model study: n=4), using the following formula: 
 (3) 
 
where the denominator (in our study: 0.33³) 
represents the ideal situation where spreading of the 
normalised Kp values is maximal, and hence 
reflecting the maximal discriminating power 
between the different formulations used in the 
study. 
There is usually an interval between the start of 
the experiment and the steady state being reached. 
This lag-time is derived from the graph of 
cumulative absorbed dose versus time: it is the 
intercept (on the time axis) of the tangent to the 
linear part of the absorption profile. 
 
Spilanthol application 
A recent study has evaluated the transdermal 
behaviour of the N-alkylamide spilanthol. Three 
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different formulations were compared on three 
different FDC test systems, differing in the receptor 
fluid (PBS, PBS + 0.5% m/V HPBCD and 
EtOH/H2O (30/70, V/V)). Full experimental details 
and the transdermal results obtained are given in 
references (18 - 19). 
 
RESULTS 
 
We used our criterion in a study evaluating the 
receptor phase composition. The solubility of the 
test compound should be sufficiently high to 
prevent slowing down the flux. Typically, the 
receptor fluids used are physiological saline or 
phosphate buffered solutions. If necessary, these 
solutions are complemented with a solubilizer. 
However, due to interactions with the skin, the 
receptor fluid itself can change the transdermal 
behaviour of the test compound. Hence, this 
operational variable in FDC tests can influence the 
discriminative power of the test system. 
 
Testosterone solubility in the receptor media 
Before starting the skin penetration studies, the 
solubility of testosterone at 32°C (i.e. the 
physiological skin temperature (5)) was determined 
for each receptor medium. Results are given in 
Table 2. Without solubilising agent added, 
testosterone solubility was very low, ranging 
between 67 and 87 µg/mL. Therefore, these media 
without solubilising agents were not used as a 
receptor fluid. Ethanol-based receptor media are 
historically quite often used in this kind of studies, 
and testosterone was highly soluble in the 
EtOH/H2O (30/70, V/V) receptor medium. 
However, because the use of organic solvents is 
considered not well-suited as a biocompatible 
receptor medium in product development and 
establishing IVIVR (20) resulting in a regulatory 
reluctance to accept these organic solvent based 
receptor media, different other physiological buffers 
were evaluated as receptor media as well. However, 
due to the very low solubility of testosterone in 
purely aqueous systems, the addition of a 
solubilising additive was required. In compliance 
with the OECD guideline 428 and considering the 
fact that a concentration of 50 g/L is generally 
accepted to be the mean albumin concentration in 
human serum (21), 5% m/V BSA was used. As an 
alternative, addition of HPBCD as a solubilizer was 
evaluated as well. The solubility of testosterone at 
32°C in PBS was determined at different HPBCD 
concentrations ranging from 0 till 5% m/V. A linear 
relationship between the testosterone solubility and 
the percentage HPBCD added was found (R² = 
0.9991).  A working concentration of 0.5% m/V 
HPBCD was chosen, as this gave solubility results 
in the range of the physiological 5% m/V BSA. The 
ratio of testosterone solubility at 32°C to the 
maximum amount of testosterone found in the 
receptor fluids of the skin and of the initial flux 
through the artificial membrane was minimally five 
(i.e. for SS + 0.5% HPBCD): this value is 
sufficiently high to assure that solubility of the 
active ingredient in the receptor phase was not the 
rate limiting step for transdermal and initial 
transmembrane penetration, which was 
experimentally confirmed by the linear kinetics. 
 
Franz diffusion cell experiments using human 
skin 
In our development of a regulatory acceptable, i.e. a 
data-supported, justified and discriminating test 
method, we used four model formulations from 
different origin/supplier/composition which are thus 
expected to show differences in their diffusion 
behaviour. Our experimental data are given in Table 
3. For all experimental conditions, a steady state 
linear part was reached (R² values ranging from 
0.9566 to 0.9971) and therefore transdermal 
parameters for each condition could be calculated 
using the previously given formulae (Figure 1). As 
two formulations have a label claim of 2 % m/m 
(Androtiv® and Tostrex®) and two formulations are 
1 % m/m (Androgel® and Testim®), the 
permeability coefficient Kp is a more appropriate 
evaluation tool compared to an absolute permeated 
quantity, as Kp takes the concentration effect into 
account. Moreover, Kp reduces all the different 
experimental points into one concentration-
standardised flux-value, contrasting a one-time-
point like e.g. the cumulative amount penetrated 
after 24 hours. When the acceptor medium 
contained BSA, the rank order of transdermal 
permeation was as follows (from high to low): 
Tostrex®, Androgel®, Androtiv® and Testim®. 
When 0.5% m/V HPBCD was present in the 
receptor chamber, Tostrex® and Androgel® still 
showed the highest permeation, but testosterone 
penetration from Androtiv® was lower than from 
Testim®. 
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Table 2. Solubility of testosterone in the different receptor media used at 32°C. 
Receptor medium Average solubility ± S.D. (µg/mL) (n = 3-6) 
EtOH/H20 (30:70, V/V) 26381 ± 403 
PBS 69 ± 16 
PBS + 5% BSA 345 ± 10 
PBS + 0.5% HPBCD 527 ± 23 
SS 67 ± 43 
SS + 0.5% HPBCD 534 ± 23 
SBF 87 ± 33 
SBF + 5% BSA 314 ± 13 
 
 
 
Figure 1. Cumulative amount of testosterone in the receptor fluid (µg) versus time (h) curves using human skin and PBS + 
HPBCD (upper panel) or PBS + BSA (lower panel) as a receptor fluid. 
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Table 3. Calculated permeation parameters (± S.D.) using different receptor media. 
Parameter Gel EtOH/H2O PBS + 5% BSA 
PBS + 0.5% 
HPBCD SBF + 5% BSA 
SS + 0.5% 
HPBCD 
Skin 
Kp 
(x 10-4 cm/h) 
Androtiv® 2.75 ± 0.10 1.07 ± 0.05 1.40 ± 0.07 1.29 ± 0.04 2.05 ± 0.07 
Androgel® 4.08 ± 0.27 3.98 ± 0.26 10.29 ± 0.81 4.14 ± 0.44 8.03 ± 0.66 
Testim® 0.50 ± 0.06 1.50 ± 0.13 4.53 ± 0.35 1.16 ± 0.13 5.89 ± 0.38 
Tostrex® 16.91 ± 0.76 6.20 ± 0.24 11.53 ± 0.50 6.73 ± 0.41 22.41 ± 0.99 
Skin 
Tlag (h) 
Androtiv® 3.13 5.44 5.48 3.64 2.77 
Androgel® 5.87 7.07 6.72 7.04 7.34 
Testim® 5.43 7.66 7.26 10.75 7.50 
Tostrex® 3.58 4.23 4.30 4.97 4.11 
Membrane 
Initial 
Kp 
(x 10-4 cm/h) 
Androtiv® 27.93 ± 0.47 2.15 ± 0.18 7.91 ± 0.69 1.42 ± 0.15 9.77 ± 1.22 
Androgel 90.16 ± 1.29 5.30 ± 0.47 5.86 ± 0.49 5.61 ± 0.61 5.95 ± 0.54 
Testim® 45.05 ± 1.02 2.62 ± 0.28 3.41 ± 0.19 4.18 ± 0.47 2.48 ± 0.15 
Tostrex® 26.81 ± 0.82 30.07 ± 0.44 45.41 ± 0.16 28.33 ± 0.20 57.10 ± 0.20 
Membrane 
Initial 
Tlag (h) 
Androtiv® 0.20 0.51 0.56 0.37 0.53 
Androgel® 0.17 0.48 0.54 0.53 0.50 
Testim® 0.11 0.63 0.42 0.32 3.63 
Tostrex® 0.09 0.21 0.26 0.31 0.23 
Membrane 
Final Kp 
(x 10-4 cm/h) 
Androtiv® 8.89 ± 0.55 7.28 ± 0.40 24.50 ± 2.71 6.93 ± 0.13 29.72 ± 0.68 
Androgel® 39.27 ± 1.31 26.55 ± 0.95 39.91 ± 2.99 27.11 ± 0.77 37.60 ± 3.87 
Testim® 28.59 ± 0.68 7.89 ± 0.33 64.04 ± 3.71 8.49 ± 0.44 56.08 ± 1.24 
Tostrex® 6.90 ± 0.49 14.81 ± 1.06 20.32 ± 0.40 21.15 ± 1.50 24.26 ± 0.76 
 
 
 
Franz diffusion cell experiments using artificial 
membranes 
In addition to the dermatomed human skin 
approach, the four formulations were tested in 
triplicate on Franz diffusion cells using an artificial 
membrane as diffusion barrier and again, the 
cumulative amount of testosterone in the receptor 
fluid was plotted against time (Figure 2). 
 
In contrast to the skin experiments, the data 
obtained could not be modelled directly over the 
complete 24 hours experimental domain by the 
standard steady-state linear regression due to the 
non-linear behaviour, with an initial linear part, a 
bending point region (22) and a final linear part. 
However, both selected linear time-regions were 
suitable for separate linear regression analysis: the 
initial 2 hours and from 8 till 24 (final) hours. 
Moderate to good linear coefficients of 
determination (R² ranging from 0.9296 to 0.9999) 
were obtained for both selected time regions and 
therefore, initial and final Kp-values were 
calculated from both experimentally obtained J 
values as before (Table 3). As expected, lag times 
for the initial linear part of the membrane studies 
were much lower compared to the human skin 
penetration behaviour.  
 
Values of the discriminating power criterion 
The calculated values for the response function 
F(Kp) are given in Table 4. Values are ranging from 
0.12%, indicating that this FDC system is not 
capable of discriminating the different formulations, 
to 28% where a different behaviour of the 
formulations could be observed. For quality control 
(QC) purposes, the systems with the highest F(Kp) 
values are preferred, as these will be the most 
discriminating.  
 
DISCUSSION 
 
Being able to consistently observe differences in 
transdermal/membrane behaviour of similar 
transdermal products is useful in quality control 
(QC) environment, where the concept of clinically 
overdiscriminating in vitro tests is superfluous: 
whenever significant differences are observed,
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Figure 2. Cumulative amount of testosterone in the receptor fluid (µg) versus time (h) curves using artificial membranes 
and PBS + HPBCD (upper panel) or PBS + BSA (lower panel) as a receptor fluid. 
 
pharmaceutical non-equivalence should be 
concluded. For this QC-objective, we were 
especially looking at the discriminating power of 
the Franz diffusion cell methods, which are 
recommended as global quality tests for transdermal 
products, similar to dissolution for oral solid dosage 
forms. To evaluate this discriminating aspect in an 
objective and quantitative way, a new criterion 
F(Kp) is proposed: the percentage equal-spread of 
the rescaled Kp values obtained in the different 
conditions investigated. We have evaluated the 
practical usefulness of this criterion in a study 
evaluating the choice of the receptor fluid.
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Table 4. F(Kp) values (percentage spreading) on normalized Kp values for the testosterone preparations investigated (n = 
4). 
Membrane System EtOH/H2O 
PBS + 5% 
BSA 
PBS + 0.5% 
HPBCD 
SBF + 5% 
BSA 
SS + 0.5% 
HPBCD 
Skin Kp 9.42 0.58 7.13 0.47 28.04 
Membrane initial Kp 3.46 0.12 0.75 0.36 2.50 
Membrane final Kp 6.23 0.74 23.18 1.75 11.85 
 
 
Table 5. F(Kp) values for different spilanthol formulations (n = 3). 
Formulation Receptor fluid Kp (10-4 cm/h) ± S.D. F(Kp) 
65% EtOH 
PBS 
4.38 ± 2.82 
14.08 10% PG 15.34 ± 1.50 
Commercial extract 3.56 ± 2.17 
65% EtOH 
PBS + HPBCD 
4.38 ± 2.84 
10.42 10% PG 16.62 ± 1.85 
Commercial extract 4.95 ± 3.31 
65% EtOH 
EtOH/H2O 
0.70 ± 0.25 
0.45 10% PG 5.46 ± 1.60 
Commercial extract 0.64 ± 0.31 
 
 
Spilanthol application 
Based upon the Kp values as experimentally 
obtained (18), the F(Kp) values were calculated for 
each of the three FDC test systems (Table 5). 
The choice of the receptor solution is indeed an 
important determinant in the design of an in vitro 
model for percutaneous penetration, as the receptor 
phase interacts directly with the membrane 
(artificial or skin) and eventually with the 
formulation in the donor phase, as well as collects 
the drug penetrated through the skin/membrane 
(23). Depending upon the test conditions chosen, 
different conclusions about the release/permeation 
characteristics of the formulation can be made (24). 
The generally accepted OECD Guideline Number 
428 on the Conduct of Skin Absorption Studies 
states that the selection of the receptor fluid must be 
compatible with the skin preparation and must meet 
the solubility requirements of the test substance (5). 
No further details on how this should be translated 
in practice are given. Therefore, researchers are free 
to choose the receptor medium they prefer for their 
selected application and intended objective. An 
overview of the most commonly used receptor 
media in recent (2007-2008) in vitro transdermal 
penetration literature studies (n=104) is given in 
Figure 3. The base solvent (left graph) is often 
supplemented by additives (right graph), mostly to 
increase the solubility of the test substance to obtain 
sink conditions or to increase the stability of the 
system. Phosphate buffers, often resembling 
physiological conditions, are the most often used 
base solvents (60%), followed by non-buffered 
water (15%) or normal saline (sodium chloride) 
solutions (15%). Often, these phosphate buffers are 
derived from and are similar to those used in 
dissolution tests for oral dosage forms (25). To 
prevent bacterial degradation of the drug under 
investigation (26), antimicrobial preservative agents 
are used as an additive in 15% of the cases. Besides 
the maintenance of skin viability and integrity, a 
major requirement of the receptor fluid is to assure 
sufficient solubility of the test substance in order for 
the solubility not to limit the penetration (27). When 
the transdermal behaviour of compounds with low 
aqueous solubility is to be assessed, different 
solubilizers can be used to increase the solubility of 
the drug in the aqueous receptor medium while 
limiting skin interaction. Solubilization of poorly 
water soluble drugs is a frequently encountered 
challenge in the pharmaceutical industry and a 
number of solubilisation techniques have been 
developed (28). The solubility of poorly water 
soluble drugs can be increased by the addition of a 
water miscible solvent in which the drug has a good 
solubility. In transdermal penetration studies, 
solubility-increasing additives are used in 36% 
(n=37) of the literature reports. In these studies,  
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Figure 3. Overview of receptor media used in transdermal penetration studies. Left: base solvents. Right: solubility-
increasing  additives. 
 
 
EtOH is most frequently used as a co-solvent 
(46%), but other solvents such as propylene glycol 
(PG) (8%), polyethylene glycol (PEG) (5%), 
isopropanol (5%), and even methanol (3%) are 
being employed. In 8% of the recent studies 
reported in the literature (period 2007-2008), 
surfactants like Tween20® or Brij98® have been 
used as a modifier to ensure adequate solubility of 
the test compound. Albumin binds a wide variety of 
hydrophobic ligands, including steroids, fatty acids, 
retinoids, thyroid hormone, prostaglandins and 
antibiotics (29). Because serum contains around 3 
to 5% m/V albumin (21), addition of similar 
quantities BSA to the receptor medium contributes 
to its in vivo relevance. It is also recommended by 
the OECD as a solubilising agent and was used in 
almost 20% of the recent studies to increase 
solubility of lipophilic compounds. Alternatively, 
cyclodextrins can be used as they possess a 
lipophilic cavity and a hydrophilic exterior, thus 
making them ideal to form inclusion complexes 
with non-polar molecules in relatively polar 
solvents like water (30). This complexation has 
been applied as one of the most useful ways to 
improve the dissolution of poorly water-soluble 
drugs in intravenous and oral formulations (31). Up 
till now, they are only scarcely used in Franz 
diffusion cell experiments (approximately 5% of the 
literature studies), but are promising as solubilizing 
agents in the field. HPBCD is a chemically 
modified cyclodextrin with high aqueous solubility 
(32). It is already successfully used in transdermal 
formulations (33), as well as in dissolution media 
for the evaluation of tablets for oral use (34). 
When using human/animal skin, interactions of 
the receptor medium with the contacting lower skin 
layers can modify these layers (e.g. precipitation of 
proteins or dissolution of specific endogenous skin 
compounds) and consequently, the apparent 
diffusion characteristics of the skin for the test 
compound can change. This is not the case when 
using artificial membranes, which remain inert 
towards the receptor medium composition. In this 
case, a more direct interaction of the receptor 
medium with the formulation itself is expected. The 
homogeneous artificial membrane is thus more a 
passive diffusion barrier only, while the 
heterogeneous skin can additionally have an active 
role. While the above considerations are important 
in IVIVR, assuring product consistency during 
development and marketing is the key concern in 
pharmaceutical quality, with no obligatory link to 
the in vivo relevance. Therefore, in the QC-field, 
tests are expected to be maximally discriminating. 
The criterion F(Kp) is a measure for the percentage 
spread of the normalised Kp values obtained in the 
different conditions investigated. It can be used to 
evaluate the discriminating effect of the FDC 
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method, i.e. the ability to distinguish different 
preparations as separate items. The maximal F(Kp) 
value that can be reached theoretically is 100%, 
meaning that the Kp-values obtained are maximally 
different. On the other hand, if the Kp-values found 
for two different preparations are identical, the test 
is not discriminating and the F(Kp) value obtained 
in this situation will be zero. In other words, the 
F(Kp) value indicates how the operational 
conditions employed during FDC experiments 
affect the ability of the test to discriminate different 
preparations. 
Using our criterion F(Kp), the lowest responses 
were obtained with the membrane initial Kp values. 
Therefore, irrespective of the receptor medium 
used, only drastic changes in the diffusion 
behaviour can be seen on initial membrane Kp 
values, while less pronounced effects are masked 
and not differentiated. Despite the fact that the 
evaluation of the initial kinetics has the advantage 
of not being influenced by solubility constraints and 
of a relatively short time period which is well suited 
for QC purposes, our criterion quantitatively shows 
this approach is not useful. When considering skin 
Kp or membrane final Kp values, a better spreading 
and hence discriminating power was observed. 
Depending upon the type of receptor medium used, 
differences in the discriminating power of the 
testosterone FDC experiments were observed 
(Table 4). The highest discriminating response was 
obtained using 0.5% HPBCD containing media (up 
to 28.04%), while the discriminative power of the 
test was relatively small when using BSA-
containing media (< 1.75%). For EtOH/H2O, the 
F(Kp) value was intermediate (up to 9.42%). A 
different situation was observed for the spilanthol 
samples (Table 5): best discriminating results were 
obtained using PBS without solubilizers as a 
receptor medium (14.08%), followed by PBS 
containing 0.5% m/V HPBCD (10.42%). When 
using EtOH/H20 (30/70, V/V), the test was not 
discriminative (0.45%). 
 
CONCLUSIONS 
 
For quality purposes of transdermal products, a 
quantitative and objective discriminative power 
criterion is proposed based upon the observed 
spreading of Kp-values. This criterion is a simple, 
reliable and reproducible characteristic that is 
experimentally obtained from the generally 
accepted Franz diffusion cell test for the assessment 
of the transdermal behaviour of molecules. The 
practical applicability was demonstrated by 
evaluating the influence of the receptor medium 
composition on the discriminative power of the test 
system for both testosterone and spilanthol 
containing formulations. The best results were 
obtained with PBS supplemented with HPBCD for 
testosterone and without HPBCD for spilanthol. 
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ECETOC European Centre for Ecotoxicology 
and Toxicology of Chemicals 
EtOH Ethanol 
FDA Food and Drug Administration 
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MeOH  Methanol 
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PEG Polyethylene Glycol 
PG Propylene Glycol 
QC Quality Control 
S.D. Standard deviation 
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